Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers; ACS Applied Materials and Interfaces; Vol. 11 (14)

গ্রন্থ-পঞ্জীর বিবরন
Parent link:ACS Applied Materials and Interfaces
Vol. 11 (14).— 2019.— [P. 13091–13104]
সংস্থা লেখক: Национальный исследовательский Томский политехнический университет Исследовательская школа химических и биомедицинских технологий (ИШХБМТ)
অন্যান্য লেখক: Timin A. S. Aleksandr Sergeevich, Peltek A. O. Aleksey Olekseevich, Zyuzin M. V. Mikhail, Muslimov A. R. Albert Radikovich, Karpov T. E. Timofey Evgenjevich, Epifanovskaya O. S.
সংক্ষিপ্ত:Title screen
An important area in modern malignant tumor therapy is the optimization of antitumor drugs pharmacokinetics. The use of some antitumor drugs is limited in clinical practice due to their high toxicity. Therefore, the strategy for optimizing the drug pharmacokinetics focuses on the generation of high local concentrations of these drugs in the tumor area with minimal systemic and tissue-specific toxicity. This can be achieved by encapsulation of highly toxic antitumor drug (vincristine (VCR) that is 20–50 times more toxic than widely used the antitumor drug doxorubicin) into nano- and microcarriers with their further association into therapeutically relevant cells that possess the ability to migrate to sites of tumor. Here, we fundamentally examine the effect of drug carrier size on the behavior of human mesenchymal stem cells (hMSCs), including internalization efficiency, cytotoxicity, cell movement, to optimize the conditions for the development of carrier-hMSCs drug delivery platform. Using the malignant tumors derived from patients, we evaluated the capability of hMSCs associated with VCR-loaded carriers to target tumors using a three-dimensional spheroid model in collagen gel. Compared to free VCR, the developed hMSC-based drug delivery platform showed enhanced antitumor activity regarding those tumors that express CXCL12 (stromal cell-derived factor-1 (SDF-1)) gene, inducing directed migration of hMSCs via CXCL12 (SDF-1)/CXCR4 pathway. These results show that the combination of encapsulated antitumor drugs and hMSCs, which possess the properties of active migration into tumors, is therapeutically beneficial and demonstrated high efficiency and low systematic toxicity, revealing novel strategies for chemotherapy in the future.
Режим доступа: по договору с организацией-держателем ресурса
ভাষা:ইংরেজি
প্রকাশিত: 2019
বিষয়গুলি:
অনলাইন ব্যবহার করুন:http://dx.doi.org/10.1021/acsami.8b22685
বিন্যাস: বৈদ্যুতিক গ্রন্থের অধ্যায়
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=660127

MARC

LEADER 00000naa0a2200000 4500
001 660127
005 20250331140402.0
035 |a (RuTPU)RU\TPU\network\29077 
090 |a 660127 
100 |a 20190426d2019 k||y0rusy50 ba 
101 0 |a eng 
102 |a US 
135 |a drcn ---uucaa 
181 0 |a i  
182 0 |a b 
200 1 |a Safe and Effective Delivery of Antitumor Drug Using Mesenchymal Stem Cells Impregnated with Submicron Carriers  |f A. S. Timin [et al.] 
203 |a Text  |c electronic 
300 |a Title screen 
330 |a An important area in modern malignant tumor therapy is the optimization of antitumor drugs pharmacokinetics. The use of some antitumor drugs is limited in clinical practice due to their high toxicity. Therefore, the strategy for optimizing the drug pharmacokinetics focuses on the generation of high local concentrations of these drugs in the tumor area with minimal systemic and tissue-specific toxicity. This can be achieved by encapsulation of highly toxic antitumor drug (vincristine (VCR) that is 20–50 times more toxic than widely used the antitumor drug doxorubicin) into nano- and microcarriers with their further association into therapeutically relevant cells that possess the ability to migrate to sites of tumor. Here, we fundamentally examine the effect of drug carrier size on the behavior of human mesenchymal stem cells (hMSCs), including internalization efficiency, cytotoxicity, cell movement, to optimize the conditions for the development of carrier-hMSCs drug delivery platform. Using the malignant tumors derived from patients, we evaluated the capability of hMSCs associated with VCR-loaded carriers to target tumors using a three-dimensional spheroid model in collagen gel. Compared to free VCR, the developed hMSC-based drug delivery platform showed enhanced antitumor activity regarding those tumors that express CXCL12 (stromal cell-derived factor-1 (SDF-1)) gene, inducing directed migration of hMSCs via CXCL12 (SDF-1)/CXCR4 pathway. These results show that the combination of encapsulated antitumor drugs and hMSCs, which possess the properties of active migration into tumors, is therapeutically beneficial and demonstrated high efficiency and low systematic toxicity, revealing novel strategies for chemotherapy in the future. 
333 |a Режим доступа: по договору с организацией-держателем ресурса 
461 |t ACS Applied Materials and Interfaces 
463 |t Vol. 11 (14)  |v [P. 13091–13104]  |d 2019 
610 1 |a электронный ресурс 
610 1 |a труды учёных ТПУ 
610 1 |a human mesenchymal stem cells 
610 1 |a silica capsules 
610 1 |a malignant tumor 
610 1 |a spontaneous and directed migration 
610 1 |a tumor spheroid 
610 1 |a tumor therapy 
610 1 |a vincristine 
610 1 |a стволовые клетки 
610 1 |a злокачественные опухоли 
610 1 |a лечение 
701 1 |a Timin  |b A. S.  |c Chemist  |c Associate Scientist of Tomsk Polytechnic University  |f 1989-  |g Aleksandr Sergeevich  |3 (RuTPU)RU\TPU\pers\37036 
701 1 |a Peltek  |b A. O.  |g Aleksey Olekseevich 
701 1 |a Zyuzin  |b M. V.  |g Mikhail 
701 1 |a Muslimov  |b A. R.  |g Albert Radikovich 
701 1 |a Karpov  |b T. E.  |g Timofey Evgenjevich 
701 1 |a Epifanovskaya  |b O. S. 
712 0 2 |a Национальный исследовательский Томский политехнический университет  |b Исследовательская школа химических и биомедицинских технологий (ИШХБМТ)  |c (2017- )  |3 (RuTPU)RU\TPU\col\23537 
801 2 |a RU  |b 63413507  |c 20190426  |g RCR 
856 4 |u http://dx.doi.org/10.1021/acsami.8b22685 
942 |c CF